3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Interventions
Temozolomide
40
Magnetic Resonance Spectroscopy
19
Radiotherapy
18
Specimen Handling
14
Radiation
12
Bevacizumab
11
Lomustine
9
pembrolizumab
6
fludarabine
5
Surgical Procedures, Operative
5
atezolizumab
4
Nivolumab
4
Ipilimumab
4
Cyclophosphamide
4
Carboplatin
4
Biopsy
4
cemiplimab
3
azeliragon
3
Immunoglobulin G
3
Disulfides
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
rocakinogene sifuplasmid
2
poly ICLC
2
olaparib
2
lutetium Lu 177 dotatate
2
durvalumab
2
dabrafenib
2
contrast agent BR1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
CLR1404
×
90 days
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled